Molecular and behavioral effects mediated by Gs-coupled adenosine A2a, but not serotonin 5-HT4 or 5-HT6 receptors following antipsychotic administration

Neuroscience

Volumn 89, Issue 3, 1999, Pages 927-938

  Ward, R P ^a   Dorsa, D M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Adenosine A2a; Antipsychotic; Catalepsy; Haloperidol; In situ hybridization; Neurotensin

Indexed keywords

ADENOSINE A2A RECEPTOR; CLOZAPINE; HALOPERIDOL; MESSENGER RNA; NEUROLEPTIC AGENT; SEROTONIN 4 RECEPTOR; SEROTONIN 6 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATALEPSY; CONTROLLED STUDY; GENE EXPRESSION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; ONCOGENE C FOS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PSYCHOSIS; RAT; RNA ANALYSIS;

ADENOSINE; ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; CAFFEINE; CATALEPSY; CLOZAPINE; CORPUS STRIATUM; CYCLIC AMP; GENE EXPRESSION REGULATION; GENES, FOS; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HALOPERIDOL; NERVE TISSUE PROTEINS; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ADENOSINE A2A; RECEPTORS, DOPAMINE D2; RECEPTORS, PURINERGIC P1; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT4; SECOND MESSENGER SYSTEMS; SEROTONIN; SEROTONIN ANTAGONISTS; THEOPHYLLINE;

EID: 0032933185     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(98)00364-9     Document Type: Article

References (58)

1. Adams M.R., Brandon E.P., Chartoff E.H., Idzerda R.L., Dorsa D.M., McKnight G.S. Loss of haloperidol induced gene expression and catalepsy in protein kinase A-deficient mice. Proc. natn. Acad. Sci. U.S.A. 94:1997;12157-12161.
2. Alexander M.J., Miller M.A., Dorsa D.M., Bullock B.P., Melloni R.H. Jr., Dobner P.R., Leeman S.E. Distribution of neurotensin/neuromedin N mRNA in rat forebrain: unexpected abundance in hippocampus and subiculum. Proc. natn. Acad. Sci. U.S.A. 86:1989;5202-5206.
3. Augood S.J., Westmore K., Emson P.C. Phenotypic characterization of neurotensin messenger RNA-expressing cells in the neuroleptic-treated rat striatum: a detailed cellular co-expression study. Neuroscience. 76:1997;763-774.
4. Baldessarini R.J., Frankenburg F.R. Clozapine. A novel antipsychotic agent. New Engl. J. Med. 324:1991;746-754.
5. Boegman R.J., Vincent S.R. Involvement of adenosine and glutamate receptors in the induction of c-fos in the striatum by haloperidol. Synapse. 22:1996;70-77.
6. Bolden C., Cusack B., Richelson E. Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J. Pharmac. exp. Ther. 260:1992;576-580.
7. 2-dopamine receptor-mediated catalepsy. Brain Res. 450:1988;403-407.
8. Chopde C.T., Hote M.S., Mandhane S.N., Muthal A.V. Glucocorticoids attenuate haloperidol-induced catalepsy through adrenal catecholamines. J. neural Transm. 102:1995;47-54.
9. Cochran B.H. Regulation of immediate early gene expression. NIDA Res. Monogr. 125:1993;3-24.
10. Decker K.P., Roy Byrne P.P., Merchant K.M. Effect of muscimol on haloperidol-induced alteration of neurotensin gene expression in the striatum and nucleus accumbens in the rat. Brain Res. 691:1995;9-17.
11. Dunn A.J., Snijders R., Hurd R.W., Kramarcy N.R. Induction of catalepsy by central nervous system administration of neurotensin. Ann. N. Y. Acad. Sci. 400:1982;345-353.
12. Egan M.F., Chrapusta S.J., Karoum F., Wyatt R.J. The effects of acute and chronic haloperidol treatment on dopamine release mediated by the medial forebrain bundle in the striatum and nucleus accumbens. Neuropsychopharmacology. 14:1996;211-223.
13. Evers B.M., Wang X., Zhou Z., Townsend C.M. Jr., McNeil G.P., Dobner P.R. Characterization of promoter elements required for cell-specific expression of the neurotensin/neuromedin N gene in a human endocrine cell line. Molec. cell. Biol. 15:1995;3870-3881.
14. Felder C.C. Muscarinic acetylcholine receptors: signal transduction through multiple effectors. Fedn Am. Socs exp. Biol. J. 9:1995;619-625.
15. Ferr'e S., Guix T., Prat G., Jane F., Casas M. Is experimental catalepsy properly measured? Pharmac. Biochem. Behav. 35:1990;753-757.
16. 2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia. Neuroscience. 63:1994;765-773.
17. Gerald C., Adham N., Kao H.T., Olsen M.A., Laz T.M., Schechter L.E., Bard J.A., Vaysse P.J., Hartig P.R., Branchek T.A.et al. The 5-HT4 receptor: molecular cloning and pharmacological characterization of two splice variants. Eur. molec. Biol. Org. J. 14:1995;2806-2815.
18. Govoni S., Hong J.S., Yang H.Y., Costa E. Increase of neurotensin content elicited by neuroleptics in nucleus accumbens. J. Pharmac. exp. Ther. 215:1980;413-417.
19. Guieu R., Couraud F., Pouget J., Sampieri F., Bechis G., Rochat H. Adenosine and the nervous system: clinical implications. Clin. Neuropharmac. 19:1996;459-474.
20. Higgins M.J., Hosseinzadeh H., MacGregor D.G., Ogilvy H., Stone T.W. Release and actions of adenosine in the central nervous system. Pharmac. World Sci. 16:1994;62-68.
21. Hoffman D.C., Donovan H. Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology, Berlin. 120:1995;128-133.
22. Jacobson K.A., Nikodijevi'c O., Padgett W.L., Gallo Rodriguez C., Maillard M., Daly J.W. 8-(3-chlorostyryl)caffeine (CSC) is a selective A2-adenosine antagonist in vitro and in vivo. Fedn Eur. biochem. Socs Lett. 323:1993;141-144.
23. 2 receptor interactions in animal models of schizophrenia. Eur. J. Pharmac. 295:1996;147-154.
24. Kapur S. 5-HT2 antagonism and EPS benefits: is there a causal connection? Psychopharmacology, Berlin. 124:1996;35-39.
25. Karoum F., Egan M.F. Dopamine release and metabolism in the rat frontal cortex, nucleus accumbens, and striatum: a comparison of acute clozapine and haloperidol. Br. J. Pharmac. 105:1992;703-707.
26. Kebabian J.W., Calne D.B. Multiple receptors for dopamine. Nature. 277:1979;93-96.
27. Klemm W.R. Evidence for a cholinergic role in haloperidol-induced catalepsy. Psychopharmacology, Berlin. 85:1985;139-142.
28. Konradi C., Heckers S. Haloperidol-induced Fos expression in striatum is dependent upon transcription factor cyclic AMP response element binding protein. Neuroscience. 65:1995;1051-1061.
29. Konradi C., Kobierski L.A., Nguyen T.V., Heckers S., Hyman S.E. The cAMP-response-element-binding protein interacts, but Fos protein does not interact, with the proenkephalin enhancer in rat striatum. Proc. natn. Acad. Sci. U.S.A. 90:1993;7005-7009.
30. 1 receptor mediated catalepsy in rats. J. neural Transm. 95:1994;123-136.
31. Lambert P.D., Gross R., Nemeroff C.B., Kilts C.D. Anatomy and mechanisms of neurotensin-dopamine interactions in the central nervous system. Ann. N. Y. Acad. Sci. 757:1995;377-389.
32. 2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum. J. comp. Neurol. 355:1995;418-426.
33. 1 receptor-mediated effects on c-fos expression. J. Neurosci. 17:1997;8038-8048.
34. MacGibbon G.A., Lawlor P.A., Bravo R., Dragunow M. Clozapine and haloperidol produce a differential pattern of immediate early gene expression in rat caudate-putamen, nucleus accumbens, lateral septum and islands of Calleja. Molec. Brain Res. 23:1994;21-32.
35. Merchant K.M., Dobner P.R., Dorsa D.M. Differential effects of haloperidol and clozapine on neurotensin gene transcription in rat neostriatum. J. Neurosci. 12:1992;652-663.
36. Merchant K.M., Dorsa D.M. Differential induction of neurotensin and c-fos gene expression by typical versus atypical antipsychotics. Proc. natn. Acad. Sci. U.S.A. 90:1993;3447-3451.
37. Merchant K.M., Miller M.A., Ashleigh E.A., Dorsa D.M. Haloperidol rapidly increases the number of neurotensin mRNA-expressing neurons in neostriatum of the rat brain. Brain Res. 540:1991;311-314.
38. Monsma F.J. Jr., Shen Y., Ward R.P., Hamblin M.W., Sibley D.R. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Molec. Pharmac. 43:1993;320-327.
39. 2 receptors. Proc. natn. Acad. Sci. U.S.A. 88:1991;3135-3139.
40. Nemeroff C.B. Neurotensin: perchance an endogenous neuroleptic? Biol. Psychiat. 15:1980;283-302.
41. Nguyen T.V., Kosofsky B.E., Birnbaum R., Cohen B.M., Hyman S.E. Differential expression of c-fos and zif268 in rat striatum after haloperidol, clozapine, and amphetamine. Proc. natn. Acad. Sci. U.S.A. 89:1992;4270-4274.
42. Ongini E., Fredholm B.B. Pharmacology of adenosine A2A receptors. Trends pharmac. Sci. 17:1996;364-372.
43. Ozaki T., Katsumoto E., Yokotani N., Yamagami S. The comparative effects of haloperidol, (-)-sulpiride, and SCH23390 on c-fos and c-jun mRNA expressions, and AP-1 DNA binding activity. Eur. Neuropsychopharmac. 7:1997;181-187.
44. Paxinos G. and Watson C. (1986) The Rat Brain in Stereotaxic Coordinates. Academic, Sydney.
45. 2 dopamine receptor mRNA in striatal output pathways following a selective lesion of striatonigral neurons. Brain Res. 631:1993;161-166.
46. Reynolds G.P. Antipsychotic drug mechanisms and neurotransmitter systems in schizophrenia. Acta psychiat. scand. 380(Suppl.):1994;36-40.
47. Robertson G.S., Matsumura H., Fibiger H.C. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J. Pharmac. exp. Ther. 271:1994;1058-1066.
48. Sanberg P.R., Bunsey M.D., Giordano M., Norman A.B. The catalepsy test: its ups and downs. Behav. Neurosci. 102:1988;748-759.
49. Schwabe U., Lorenzen A., Grun S. Adenosine receptors in the central nervous system. J. neural Transm. 34(Suppl.):1991;149-155.
50. Shibata K., Yamada K., Furukawa T. Possible neuronal mechanisms involved in neurotensin-induced catalepsy in mice. Psychopharmacology, Berlin. 91:1987;288-292.
51. Snijders R., Kramarcy N.R., Hurd R.W., Nemeroff C.B., Dunn A.J. Neurotensin induces catalepsy in mice. Neuropharmacology. 21:1982;465-468.
52. Taussig R., Gilman A.G. Mammalian membrane-bound adenylyl cyclases. J. biol. Chem. 270:1995;1-4.
53. Tune L., Coyle J.T. Serum levels of anticholinergic drugs in treatment of acute extrapyramidal side effects. Archs gen. Psychiat. 37:1980;293-297.
54. Ullmer C., Engels P., Abdel'Al S., Lubbert H. Distribution of 5-HT4 receptor mRNA in the rat brain. Naunyn-Schmiedeberg's Arch. Pharmac. 354:1996;210-212.
55. Wadenberg M.L., Ahlenius S. Antagonism by the 5-HT2A/C receptor agonist DOI of raclopride-induced catalepsy in the rat. Eur. J. Pharmac. 294:1995;247-251.
56. Ward R.P., Dorsa D.M. Colocalization of serotonin receptor subtypes 5-HT2A, 5-HT2C, and 5-HT6 with neuropeptides in rat striatum. J. comp. Neurol. 370:1996;405-414.
57. Ward R.P., Hamblin M.W., Lachowicz J.E., Hoffman B.J., Sibley D.R., Dorsa D.M. Localization of serotonin subtype 6 receptor messenger RNA in the rat brain by in situ hybridization histochemistry. Neuroscience. 64:1995;1105-1111.
58. Zorn S.H., Jones S.B., Ward K.M., Liston D.R. Clozapine is a potent and selective muscarinic M4 receptor agonist. Eur. J. Pharmac. 269:1994;R1-R2.